Control group : LAENNEC subcutaneous injection (4 ml)
Experimental group : LAENNEC intravenous injection (10 ml)
At the time of screening, 19 or 70 years
Those who have been diagnosed with alcoholic or non-alcoholic fatty liver disease
Those who have increased ALT level (Increased ALT level : 60 IU/L ≤ ALT ≤ 200 IU/L)
A person who can complete the signature agreement and comply with clinical trial requirements.
If you have the following disease
Liver cancer or other malignant tumor within 5 years at screening point
Esophageal varix bleeding, hepatic coma, ascites etc. related disease or Child-Pugh Score Class B,C patient within 1 year at screening point
Organs or bone marrow transplant experience